Evaxion Unveils AI-Designed Polio Vaccine Concepts at World Vaccine Congress
Event summary
- Evaxion will present novel AI-designed polio vaccine concepts at the World Vaccine Congress on April 1, 2026.
- The concepts, developed with the Gates Foundation, include hybrid capsid designs and de novo B-cell antigen approaches.
- Evaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus on April 2, 2026.
- Current polio vaccines have shortcomings, and Evaxion aims to create a next-generation vaccine combining the strongest aspects of existing ones.
The big picture
Evaxion's presentation at the World Vaccine Congress highlights the growing intersection of AI and vaccine development, particularly for infectious diseases with existing but imperfect vaccines. The collaboration with the Gates Foundation underscores the strategic importance of AI in global health initiatives. The success of Evaxion's approach could set a precedent for how AI is integrated into future vaccine design and development processes.
What we're watching
- AI Validation
- Whether Evaxion's AI-Immunology™ platform can consistently deliver superior vaccine designs across different viral diseases.
- Collaboration Opportunities
- The pace at which Evaxion can secure additional partnerships for its AI-designed vaccine concepts.
- Regulatory Pathways
- How quickly Evaxion can advance its novel polio vaccine concepts through clinical trials and regulatory approvals.
Our editorial coverage:
Related topics